QAM
VRTX icon

QCI Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

QCI Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-80
Closed -$9K – 681
2017
Q1 		$9K Buy
+80
New +$7.04K ﹤0.01% 408

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

QCI Asset Management's VRTX Position: Q2 2017 in Review

QCI Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 80 shares — an estimated $9K sold.

QCI Asset Management first reported a position in VRTX in Q1 2017 and held it in 1 quarter. The position peaked at $9K in Q1 2017. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • QCI Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • QCI Asset Management sold 80 Vertex Pharmaceuticals shares in Q2 2017, an estimated $9K.
  • QCI Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • QCI Asset Management's Vertex Pharmaceuticals position peaked at $9K in Q1 2017.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on QCI Asset Management's 13F filing for Q2 2017, filed 8 Aug 2017.